Cellulitis is an acute bacterial infection of the dermis and subcutaneous tissue that usually presents with expanding erythema, warmth, tenderness, and edema. Although commonly managed in ambulatory settings, it is a high-error diagnosis: venous stasis dermatitis, inflammatory edema, contact dermatitis, gout, deep vein thrombosis (DVT), abscess, and other conditions may closely resemble infection. A rigorous approach to cellulitis urgent care evaluation therefore depends as much on identifying mimics and occult complications as on selecting an antibiotic.[1,4]

Clinical overview

Most uncomplicated, nonpurulent cellulitis is caused by beta-hemolytic streptococci; Staphylococcus aureus, usually methicillin-susceptible, may contribute in selected cases. Cellulitis is a diffuse infection without a drainable collection. A pustule, spontaneous purulent drainage, fluctuant mass, or focal point of maximal tenderness should prompt reconsideration of the diagnosis and assessment for abscess, septic bursitis, infected cyst, or another suppurative process. Drainage—not antibiotics alone—is central to abscess management.[1,2]

Clinical severity is determined by systemic illness, speed of progression, pain severity, anatomic site, host factors, ability to take oral medication, likelihood of follow-up, and concern for deeper infection. Urgent care is appropriate for selected stable patients with mild nonpurulent disease; emergency department (ED) transfer is appropriate when sepsis, necrotizing infection, orbital involvement, rapidly progressive disease, or a need for advanced imaging, parenteral therapy, surgical consultation, or inpatient monitoring is suspected.[1]

Etiology and risk factors

Cellulitis often follows an imperceptible breach in the skin barrier. Ask specifically about trauma, shaving, insect bites, punctures, ulcers, fissured toe webs, eczema, tinea pedis, recent surgery, injection drug use, and bites. Lower-extremity disease is associated with chronic edema, lymphedema, venous insufficiency, obesity, and prior episodes. Diabetes, peripheral arterial disease, neuropathy, immunosuppression, and chronic wounds increase both diagnostic complexity and the risk of poor outcomes.[1,2]

Exposure history changes the likely microbiology and disposition. Water exposure, animal or human bites, penetrating trauma through footwear, burns, postoperative wounds, neutropenia, and severe immunocompromise may require culture, broader therapy, specialist input, or ED evaluation rather than routine uncomplicated-cellulitis treatment.[1,2]

Typical clinical presentation

Typical cellulitis is unilateral and develops over hours to several days. Findings include ill-defined erythema, warmth, tenderness, swelling, and sometimes regional lymphangitis or lymphadenopathy. Fever, chills, malaise, tachycardia, and leukocytosis may occur but are not required. Erysipelas is often more superficial, bright red, and sharply demarcated; management principles overlap.

On darker skin tones, erythema may be subtle or difficult to assess. Compare with the contralateral side and document warmth, edema, tenderness, induration, skin texture, drainage, and functional change rather than relying on redness alone. When practical, outline the involved area with a skin marker and document date and time; serial photographs with appropriate consent and institutional privacy safeguards can support reassessment.[3]

Focused history

• Time of onset, rate of spread, preceding lesion, trauma, wound, surgery, bite, injection, or water exposure.
• Local symptoms: pain severity, pruritus, drainage, fluctuance, blistering, numbness, weakness, reduced range of motion, or pain with passive movement.
• Systemic symptoms: fever, rigors, vomiting, confusion, dizziness, syncope, or poor oral intake.
• Prior cellulitis, abscesses, MRSA infection or colonization, recent hospitalization, recent antibiotics, or household MRSA exposure.
• Diabetes, vascular disease, lymphedema, venous disease, neuropathy, chronic kidney or liver disease, malignancy, neutropenia, transplant status, biologic therapy, and systemic corticosteroid use.
• Medication list, renal function when known, anticoagulants, pregnancy or lactation status, and a detailed allergy history. Distinguish intolerance from immediate hypersensitivity, anaphylaxis, angioedema, severe cutaneous adverse reaction, or a remote nonurticarial rash.
• For a swollen leg, assess DVT risk factors: prior venous thromboembolism, active cancer, recent surgery or immobilization, pregnancy/postpartum status, estrogen exposure, and unilateral calf symptoms.

Focused examination

Record full vital signs and general appearance before focusing on the skin. Examine and palpate the entire affected region, adjacent joints, regional lymph nodes, and the contralateral limb. Measure or estimate dimensions. Look for portal of entry, interdigital maceration, ulcers, foreign body, eschar, bullae, crepitus, necrosis, drainage, fluctuance, lymphangitis, and disproportionate tenderness.

Perform and document neurovascular assessment when an extremity is involved: distal pulses when clinically relevant, capillary refill, sensation, motor function, and compartment firmness. Evaluate joint range of motion and pain with active and passive movement when infection overlies or is near a joint. Examine feet carefully in lower-extremity presentations, including between toes, for tinea, fissures, and maceration.[1,2]

Differential diagnosis

• Abscess, furuncle, infected epidermoid cyst, or septic bursitis: focal fluctuance, purulence, a palpable cavity, or focal tenderness may be present. These are not simple nonpurulent cellulitis.
• Venous stasis dermatitis, lipodermatosclerosis, and lymphedema: often chronic, bilateral or recurrent, pruritic, scaling, hyperpigmented, or associated with longstanding edema.
• Contact dermatitis or arthropod reaction: pruritus, vesiculation, sharply patterned exposure, or a central punctum may favor a noninfectious process.
• DVT or superficial thrombophlebitis: unilateral swelling and tenderness may overlap; obtain definitive venous imaging when pretest probability warrants it.
• Crystal arthritis, septic arthritis, or inflammatory arthritis: joint-centered pain, effusion, and painful restricted passive range of motion require careful assessment.
• Herpes zoster: dermatomal pain with grouped vesicles.
• Osteomyelitis, diabetic foot infection, ischemia, and pressure injury: consider in chronic ulcers, neuropathy, exposed bone, deep wounds, or vascular compromise.

There is no single confirmatory test for cellulitis, and diagnostic error is frequent. A systematic review found that many alternative diagnoses were noninfectious, particularly stasis dermatitis, eczematous dermatitis, and edema/lymphedema. Reassessment is therefore a clinical safety intervention, not merely a treatment-failure check.[4]

Must-not-miss diagnoses and emergency red flags

Transfer to an ED by emergency medical services when clinically indicated; do not delay transfer for outpatient testing or oral treatment if any of the following are present:

• Hypotension, altered mental status, toxic appearance, persistent tachycardia, tachypnea, hypoxia, rigors, or other sepsis physiology.
• Pain out of proportion to examination, rapidly advancing erythema or edema, skin anesthesia, dusky discoloration, hemorrhagic bullae, crepitus, necrosis, or gas on imaging: concern for necrotizing soft-tissue infection.
• Periorbital or orbital symptoms, including pain with eye movement, ophthalmoplegia, proptosis, vision change, severe headache, or toxic appearance.
• Suspected septic arthritis, flexor tenosynovitis, deep hand-space infection, compartment syndrome, osteomyelitis, ischemic limb, or an infected diabetic foot with deep tissue involvement.
• Rapid progression despite appropriate initial therapy; inability to tolerate oral medication; uncontrolled pain; major functional impairment; or unreliable access to timely reassessment.
• Severe immunocompromise, severe neutropenia, major trauma, bite injury with significant infection, immersion injury, or concern for unusual organisms.

Necrotizing infection is primarily a clinical diagnosis. Normal early laboratory values, lack of fever, or absence of crepitus does not reliably exclude it. Obtain urgent surgical evaluation and emergency transfer when suspected.[1]

Diagnostic approach and point-of-care testing

Uncomplicated cellulitis is generally a clinical diagnosis. Routine wound cultures, skin aspirates, biopsies, and blood cultures are not recommended for typical nonpurulent cases because yield is low and results seldom change outpatient care. Culture purulent drainage whenever feasible and consider blood cultures or targeted microbiologic testing in severe systemic illness, immunocompromise, animal bites, immersion injuries, or other atypical exposures.[1,2]

Point-of-care ultrasound (POCUS) is useful when physical examination cannot confidently distinguish cellulitis from abscess. Cobblestoning supports interstitial edema but is not specific for infection; a discrete fluid collection, posterior enhancement, or internal debris supports abscess. POCUS should be performed only by clinicians trained and credentialed under local policy. A negative scan does not exclude deep infection, early abscess, DVT, septic arthritis, or necrotizing infection.[5]

Obtain targeted tests when they will change disposition or treatment. Examples include point-of-care glucose in patients with diabetes or systemic illness; pregnancy testing when it affects medication or imaging decisions; complete blood count, metabolic panel, lactate, blood cultures, radiography, formal vascular ultrasound, CT, or MRI in patients being transferred or evaluated for complication. Do not use a normal white blood cell count or normal inflammatory marker as reassurance when the examination suggests a deep or severe infection.

Outpatient management

Supportive measures

• Elevate the involved extremity when feasible and encourage movement within pain and safety limits.
• Address the portal of entry: cleanse superficial wounds, provide appropriate wound care, and treat toe-web fissuring, maceration, or tinea pedis when present.
• Use analgesia appropriate to the patient’s comorbidities and medication profile. Acetaminophen is often an option; nonsteroidal anti-inflammatory drugs require individualized assessment for renal disease, gastrointestinal risk, anticoagulation, heart failure, and pregnancy.
• Mark the border and arrange a defined reassessment plan. Early extension across the border can occur despite appropriate therapy, but rapid progression or systemic deterioration is not expected and requires reassessment.

Antibiotic selection

For mild, uncomplicated nonpurulent cellulitis, choose an oral agent active against streptococci. In the United States, cephalexin is a common outpatient option when there is no serious beta-lactam allergy. IDSA recommends a 5-day course for most patients, extending only when clinical improvement is inadequate. Local antibiograms, prior cultures, allergy phenotype, renal function, exposure history, and formulary availability should guide selection.[1,2]

• Cephalexin: common adult regimen for uncomplicated nonpurulent cellulitis is 500 mg orally every 6 hours for 5 days; some clinicians use 500 mg orally every 8 hours depending on local protocol and patient factors. It covers streptococci and methicillin-susceptible S. aureus, not MRSA. Renally adjust; labeling limits the daily dose to 1 g when creatinine clearance is 30–59 mL/min and provides lower-dose schedules for more severe renal impairment. Avoid in known cephalosporin hypersensitivity and carefully evaluate a history of immediate severe beta-lactam reaction. Counsel regarding rash, anaphylaxis symptoms, and antibiotic-associated diarrhea; review metformin and probenecid use. The product label lists pediatric dosing for children older than 1 year as 25–50 mg/kg/day orally in divided doses, with 50–100 mg/kg/day for severe infections; use a current pediatric reference for indication-specific interval and maximum dose rather than extrapolating from adult treatment.[6]
• Clindamycin: may be considered when an oral agent with both streptococcal and community-associated MRSA activity is needed and susceptibility supports use, or when beta-lactams cannot be used. A typical adult regimen is 300–450 mg orally every 6–8 hours for about 5 days, individualized to severity and local guidance. It carries a meaningful risk of Clostridioides difficile infection; counsel patients to seek care for significant or persistent diarrhea. Consider hepatic impairment, prior C. difficile, and local clindamycin resistance, including inducible resistance when cultures are available.
• Doxycycline: a typical adult MRSA-active regimen is 100 mg orally twice daily for about 5 days. Doxycycline has unreliable streptococcal activity; when used for a nonpurulent presentation in which both MRSA and streptococcal coverage are desired, pair it with an appropriate beta-lactam if the patient can take one, rather than using doxycycline alone. Avoid routine use during pregnancy and generally avoid in children younger than 8 years unless a specific indication outweighs risk. Counsel regarding photosensitivity, esophagitis prevention with water and upright administration, and separation from polyvalent cations.
• Trimethoprim-sulfamethoxazole (TMP-SMX): a common adult MRSA-active regimen is 1–2 double-strength tablets (160 mg/800 mg each) orally twice daily for about 5 days, with the exact regimen individualized. It also has unreliable streptococcal coverage, so pair with a streptococcal-active agent when both are required. Renal dose adjustment and monitoring considerations are important. Review sulfonamide allergy, pregnancy timing, folate status, kidney disease, hyperkalemia risk, and interacting medicines such as ACE inhibitors, angiotensin receptor blockers, spironolactone, and warfarin.
• Amoxicillin-clavulanate: is not a routine first-line choice for ordinary nonpurulent cellulitis but is often appropriate for infected animal or human bites because aerobic and anaerobic coverage is needed. A common adult regimen is 875 mg/125 mg orally every 12 hours, with duration and renal adjustment determined by wound severity and local guidance. Do not use as a substitute for MRSA coverage when MRSA is the primary concern.[1]

Routine addition of TMP-SMX to cephalexin for uncomplicated cellulitis without abscess or purulent drainage did not improve clinical resolution in a large randomized trial. MRSA-active therapy should therefore be deliberate rather than reflexive. IDSA identifies penetrating trauma, MRSA infection elsewhere or colonization, injection drug use, and systemic inflammatory response as settings that increase concern for MRSA; illness of this severity often warrants ED-level assessment rather than routine urgent-care oral therapy.[1,7]

Pregnancy, pediatrics, older adults, and organ impairment: In pregnancy, confirm the diagnosis and coordinate with obstetric care when disease is moderate, rapidly progressive, facial, recurrent, or associated with systemic symptoms. Beta-lactams are often preferred when appropriate; avoid assuming that doxycycline or TMP-SMX is suitable without gestational-age-specific review. Pediatric cellulitis requires weight-based dosing, maximum-dose verification, and lower thresholds for ED referral in infants, toxic-appearing children, facial/periorbital disease, rapid progression, immunocompromise, or concern for nonaccidental trauma. In older adults, assess renal function, delirium risk, adherence, fall risk, vascular disease, polypharmacy, and the possibility of noninfectious edema or dermatitis. Independently verify renal and hepatic dosing, drug interactions, contraindications, and local resistance patterns before prescribing any regimen.

Procedures

Do not perform incision and drainage for cellulitis without a drainable collection. If POCUS or examination identifies an abscess, manage it as an abscess under a separate procedure protocol with consent, analgesia/anesthesia, sterile preparation, drainage, culture when indicated, wound care, and documented reassessment. Do not attempt routine urgent-care drainage of suspected deep hand-space infection, infection near critical neurovascular structures, perirectal or genital infection, suspected necrotizing infection, deep or complex abscess, or abscess in a patient requiring procedural sedation or surgical consultation.

Disposition, follow-up, and expected course

Outpatient care is reasonable when the patient is hemodynamically stable, does not have altered mental status or systemic inflammatory response, can take and absorb oral medication, has no concern for deeper infection, and can obtain prompt follow-up.[1] Arrange reassessment in 24–48 hours for patients with diagnostic uncertainty, substantial edema, borderline severity, high-risk comorbidity, or any concern about progression; otherwise, instruct patients to seek reassessment if symptoms do not begin improving within 48–72 hours. The involved skin may remain discolored, swollen, or tender after antibiotics are completed; improvement in pain, warmth, spread, and systemic symptoms is more informative than immediate disappearance of erythema.[3]

At reassessment, confirm adherence, evaluate vital signs, compare with marked borders or photographs, and reconsider the diagnosis. Apparent treatment failure may reflect abscess, incorrect diagnosis, inadequate source control, nonadherence, resistant or unusual pathogen, persistent edema, arterial disease, or a deep infection requiring imaging or specialty evaluation.

Return and emergency precautions

Provide explicit written precautions. Patients should seek urgent reassessment immediately for fever or rigors, fainting, confusion, rapidly spreading redness, worsening swelling, severe or disproportionate pain, new bullae, purple/black discoloration, numbness, weakness, vomiting or inability to take medication, new drainage, or no meaningful improvement within the specified follow-up interval. Instruct patients with facial or periorbital symptoms, vision change, pain with eye movement, hand dysfunction, or a cold/pale extremity to seek emergency care immediately.

Documentation considerations

• Onset, progression, portal of entry, exposure history, prior episodes, antibiotic/MRSA history, and relevant comorbidities.
• Vital signs, systemic appearance, lesion location and measurements, skin descriptors, presence or absence of purulence/fluctuance/crepitus/bullae/necrosis, neurovascular status, joint findings, and toe-web examination when relevant.
• Differential diagnosis and why DVT, abscess, necrotizing infection, septic joint, dermatitis, or other key alternatives are less or more likely.
• Testing performed, POCUS findings when used, culture source if obtained, and rationale for not obtaining routine cultures or labs when appropriate.
• Antibiotic rationale, allergy assessment, renal/hepatic considerations, interaction review, pregnancy considerations when relevant, supportive treatment, border marking, follow-up interval, and specific ED precautions.

Clinical takeaways

• Cellulitis is a clinical diagnosis; actively look for mimics and occult abscess rather than treating every red swollen extremity as infection.
• Nonpurulent cellulitis generally requires streptococcal coverage, not automatic MRSA coverage.
• Purulence or a fluid collection changes the problem: source control becomes central.
• Sepsis, pain out of proportion, rapidly progressive change, bullae, necrosis, orbital findings, deep-structure concern, or severe host vulnerability requires emergency escalation.
• A carefully documented 24–72 hour reassessment plan is essential to safe urgent-care management.

References

1. Stevens DL, Bisno AL, Chambers HF, Dellinger EP, Goldstein EJC, Gorbach SL, et al. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America. Clin Infect Dis. 2014;59(2):e10-e52. doi:10.1093/cid/ciu296.
2. Centers for Disease Control and Prevention. Clinical guidance for group A streptococcal cellulitis [Internet]. Atlanta (GA): CDC; 2025 Aug 5 [cited 2026 Aug 16].
3. National Institute for Health and Care Excellence. Cellulitis and erysipelas: antimicrobial prescribing. NICE guideline NG141 [Internet]. London: NICE; 2019 Sep 27 [cited 2026 Aug 16].
4. Nightingale R, Yadav K, Hamill L, Glasziou P, Scott AM, Clark J, et al. Misdiagnosis of uncomplicated cellulitis: a systematic review and meta-analysis. J Gen Intern Med. 2023;38(10):2396-2404. doi:10.1007/s11606-023-08229-w.
5. American College of Emergency Physicians. Ultrasound guidelines: emergency, point-of-care, and clinical ultrasound guidelines in medicine. Ann Emerg Med. 2023;81(3):e1-e29.
6. Cephalexin capsule [prescribing information]. DailyMed [Internet]. Bethesda (MD): National Library of Medicine; revised 2026 Jul [cited 2026 Aug 16].
7. Moran GJ, Krishnadasan A, Mower WR, Abrahamian FM, LoVecchio F, Steele MT, et al. Effect of cephalexin plus trimethoprim-sulfamethoxazole vs cephalexin alone on clinical cure of uncomplicated cellulitis: a randomized clinical trial. JAMA. 2017;317(20):2088-2096. doi:10.1001/jama.2017.5653.

Educational disclaimer: This article is intended for clinician education and does not replace patient-specific clinical judgment, local protocols, specialist consultation, drug labeling, or current guidelines. Medication doses, contraindications, interactions, renal/hepatic adjustments, pediatric maximum doses, pregnancy considerations, and local resistance data must be independently verified before clinical use.